Biocon Initiates Talks For Potential Stake Sale In Biosimilar Arm & Syngene | Et Now Exclusive

Biocon Initiates Talks for Potential Stake Sale in Biosimilar Arm & Syngene | ET Now Exclusive

Biocon Biologics is well-placed to take advantage of opportunities in the biosimilars space: CEO

CNBC International News

Biocon Biologics: Revolutionizing Healthcare with Biosimilars

Biocon Biologics

Biocon Launches Biosimilar Adalimumab In US Market, Drug Used For Arthritis, Skin Disorders

Treatment Persistence and Switching Patterns of an Adalimumab Biosimilar

Strong Biosimilar Growth Powers Biocon | Trading Hour | CNBC TV18

Counting down to #Biocon’s API customer portal 'BioConnect launch!

Press Meet: Biocon Biologics To Acquire Viatris' Biosimilars Business For Global Leadership

Biocon Biologics

Biocon's Kiran Mazumdar Shaw On Strong Q4, Biosimilar Business & FY24 Outlook | Halftime Report

Biocon Rallies On FDA's Letter On Mylan's Biosimilar

Biocon Biologies IPO, Debt Reduction Strategy & More | Kiran Mazumdar-Shaw & Peter Bains

Biocon Biologics: Enabling Equitable Access to Affordable Healthcare

Biocon Biologics

Biocon Biologics to Acquire Viatris Global Biosimilars Assets for upto USD 3.335 bn in stock & cash

Biocon Biologics

How Are Biosimilars Approved? | Breaking Down Biosimilars

Global Healthy Living Foundation

Will increased biosimilar use benefit the U.S. health care system?

Biosimilars Council

Understand #biosimilar interchangeability!

Dr. Robson Discusses Differences Between Biosimilars and Biologics in Oncology

Biosimilars: Meeting functional requirements

FAQs on BMCA-Targeted Bispecific Antibodies in Multiple Myeloma

Multiple Myeloma Research Foundation - MMRF